These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17306936)

  • 21. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
    Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
    Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
    Jeremić B; Miličić B; Milisavljevic S
    Cancer; 2011 Jul; 117(13):2995-3003. PubMed ID: 21692056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
    Sorensen M; Lassen U; Palshof T; Jensen BB; Johansen J; Jensen PB; Langer SW
    Lung Cancer; 2008 May; 60(2):252-8. PubMed ID: 18036701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer].
    Bozóky G; Ruby E; Góhér I; Gábor G; Mohos A; Lengyel M
    Orv Hetil; 2005 Jul; 146(27):1433-8. PubMed ID: 16089103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.
    Jeremic B; Shibamoto Y
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):303-8. PubMed ID: 8567330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
    Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment prognostic factors in patients with early-stage (I/II) non-small-cell lung cancer treated with hyperfractionated radiation therapy alone.
    Jeremić B; Milicić B; Dagović A; Acimović L; Milisavljević S
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1112-9. PubMed ID: 16682148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical efficacy of concurrent carboplatin, etoposide, and definitive radiotherapy for stage III non-small-cell lung cancer: consideration as to therapeutic outcomes and morbidity].
    Kodaira T; Yamakawa K; Taniguchi H; Matsubara K; Ishigaki T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Aug; 58(9):497-502. PubMed ID: 9778935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy.
    Semrau S; Klautke G; Virchow JC; Kundt G; Fietkau R
    Respir Med; 2008 Feb; 102(2):210-8. PubMed ID: 17980571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.
    Yuan S; Sun X; Li M; Yu J; Ren R; Yu Y; Li J; Liu X; Wang R; Li B; Kong L; Yin Y
    Am J Clin Oncol; 2007 Jun; 30(3):239-44. PubMed ID: 17551299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients.
    Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
    Am J Clin Oncol; 2004 Aug; 27(4):350-60. PubMed ID: 15289727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial.
    De Ruysscher D; Bremer RH; Koppe F; Wanders S; van Haren E; Hochstenbag M; Geeraedts W; Pitz C; Simons J; ten Velde G; Dohmen J; Snoep G; Boersma L; Verschueren T; van Baardwijk A; Dehing C; Pijls M; Minken A; Lambin P
    Radiother Oncol; 2006 Sep; 80(3):307-12. PubMed ID: 16949169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.